AAD and HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines

The American Academy of Dermatology and the Hidradenitis Suppurativa Foundation have issued their first joint guidelines of care for hidradenitis suppurativa, a chronic inflammatory condition of the terminal follicular epithelium (the hair-follicle lining) that presents with painful nodules, abscesses and sinus tracts, most often in axillary and inguinal skin folds.

This is the first time the two organizations have collaborated on a single care document for the disease. Joint issuance matters for a field in which guidance has historically been fragmented across separate society publications. Whether the new document consolidates or merely restates prior recommendations remains to be verified against the full text; the announcement itself does not detail its contents.

Why joint guidance matters now

Hidradenitis suppurativa affects an estimated patient population that dermatology literature places at up to one percent or more of adults, though the announcement does not cite prevalence figures. Diagnostic delay remains a recognized problem, with patients frequently treated for recurrent boils or infections for years before referral to dermatology.

The guidelines arrive from the two bodies most central to the disease in the United States: the American Academy of Dermatology, the specialty's principal guideline-issuing organization, and the Hidradenitis Suppurativa Foundation, the patient-and-clinician organization dedicated solely to the condition. A unified document reduces the risk that clinicians receive divergent signals on workup severity staging, referral thresholds and treatment sequencing.

The announcement does not specify which severity instrument the guidelines adopt — Hurley staging (the three-stage system classifying disease extent) or the more granular IHS4 score — nor whether the document addresses biologics dosing. Those omissions will shape how practicing dermatologists judge its practical value.

What the collaboration signals

Co-issued guidelines typically reflect an attempt to close the gap between specialist recommendations and patient-organization priorities: access, earlier diagnosis and insurance coverage of advanced therapies. Anakinra, adalimumab and newer interleukin inhibitors have altered the treatment landscape, and payer policies on these agents vary considerably.

The announcement, distributed through Newswise, does not quote named authors or guideline chairs, and it does not state the number of recommendations, the strength-of-evidence grading system used, or a publication date in a peer-reviewed journal. Each of these details will determine whether the document carries the evidentiary weight clinicians expect from Academy-level guidance.

A caveat accompanies every such release: a guideline's value lies in its specifics, and until dermatologists can review the graded recommendations themselves, the significance of this first joint issuance rests on institutional alignment rather than on any single clinical claim. The full text's handling of treatment ladders, surgical indications and comorbidity screening — metabolic syndrome and inflammatory bowel disease among them — will be the measure against which the field assesses this collaboration.